NCT04396119

Brief Summary

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2020

Completed
11 days until next milestone

Study Start

First participant enrolled

February 11, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 13, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 13, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 20, 2020

Completed
Last Updated

September 3, 2020

Status Verified

September 1, 2020

Enrollment Period

2 months

First QC Date

January 31, 2020

Last Update Submit

September 2, 2020

Conditions

Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Explore survivors' attitudes towards lung cancer and lung cancer screening

    Semi-structured interviews

    6 months

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants who have previously been treated for Hodgkin lymphoma without evidence of relapse for at least 5 years

You may qualify if:

  • Details held in the ADAPT database at The Christie NHS Foundation trust
  • Responded to most recent ADAPT study questionnaire (April - August 2019)
  • Aged 18-80
  • Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
  • Able to provide informed consent
  • Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

You may not qualify if:

  • Previous or current diagnosis of lung cancer
  • Stated within 2019 health questionnaire that they did not wish to be contacted
  • Have participated in lung cancer screening through the Manchester Lung Health Checks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom

Location

MeSH Terms

Conditions

Hodgkin Disease

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 31, 2020

First Posted

May 20, 2020

Study Start

February 11, 2020

Primary Completion

April 13, 2020

Study Completion

April 13, 2020

Last Updated

September 3, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

It is not intended to share IPD with other researchers outside the study team

Locations

GB(1)